Interspecies Scaling: Predicting Pharmacokinetic Parameters of Antiepileptic Drugs in Humans from Animals with Special Emphasis on Clearance

doi:10.1021/js950400y

Journal of Pharmaceutical Sciences

Volume 85, Issue 4, April 1996, Pages 411-414

https://doi.org/10.1021/js950400y Get rights and content

Abstract

The objective of this study was to test the interspecies-scaling approach in a series of antiepileptic drugs. Clearance, volume of distribution, and elimination half-life were scaled up from animal data obtained from literature. Four different methods were utilized to generate plots to scale up the clearance values: (i) clearance vs body weight (simple allometric equation); (ii) the product of clearance and maximum life-span potential (MLP) vs body weight (an approach recommended in literature); (iii) the two-term power equation which incorporates both body weight and brain weight suggested by Boxenbaum; and (iv) the product of clearance and brain weight vs body weight (a new approach being introduced in this study). When the predicted values for clearance were qualitatively compared with the observed values in humans, it was found that our proposed method predicted the clearance better than the other three methods. Using the simple allometric equation, the prediction of volume of distribution as a function of body weight was found to be satisfactory. The elimination half-life could not be predicted from simple allometric equations for any of the drugs studied; however, utilizing the equation CL = VK, prediction for half-life was feasible. The results of this study indicate that it is possible to predict reliably the pharmacokinetic parameters of these antiepileptic drugs in humans from animal data using an allometric approach.

References and Notes (24)

J. Mordenti
J. Pharm. Sci.
(1986)
J. Mordenti
J. Pharm. Sci.
(1985)
H. Boxenbaum
J. Pharm. Sci.
(1986)
R.L. Dedrick
J. Pharmacokinet. Biopharm.
(1973)
H. Boxenbaum
J. Pharmacokinet. Biopharm.
(1982)
H. Boxenbaum
Drug Metab. Rev.
(1984)
P.J. McNamara
G. Sacher
W. Loscher
J. Pharmacol. Exp. Ther.
(1978)
U. Klotz et al.
J. Pharmacol. Exp. Ther.
(1976)

M.A. EL Sayed et al.

Arch. Int. Pharma-codyn.

(1978)

K. Bachmann

J. Appl. Toxicol.

(1989)

Cited by (93)

Virtual population pharmacokinetic using physiologically based pharmacokinetic model for evaluating bioequivalence of oral lacidipine formulations in dogs
2017, Asian Journal of Pharmaceutical Sciences
The aim of the present study was to investigate virtual population pharmacokinetic using physiologically based pharmacokinetic (PBPK) model for evaluating bioequivalence of oral lacidipine formulations in dogs. The dissolution behaviors of three lacidipine formulations including one commercial product and two self-made amorphous solid dispersions (ASDs) capsules were determined in 0.07% Tween 80 media. A randomized 3-period crossover design in 6 healthy beagle dogs after oral administration of the three formulations at a single dose of 4 mg was conducted. The PBPK modeling was utilized for the virtual bioequivalence study. In vitro dissolution experiment showed that the dissolution behaviors of lacidipine amorphous solid dispersions (ASDs) capsules, which was respectively prepared by HPMC-E5 or Soluplus, as polymer displayed similar curves compared with the reference formulation in 0.07% Tween 80 media. In vivo pharmacokinetics experiments showed that three formulations had comparable maximum plasma drug concentration (C_max), and the time (T_max) to reach C_max of lacidipine tablet, which was prepared by Soluplus, as polymer was slower than other two formulations in consistency with the in vitro dissolution rate. The 90% confidence interval (CI) for the C_max, AUC_0–24 h and AUC_0–∞ of the ratio of the test drug to the referencedrug exceeded the acceptable bioequivalence (BE) limits (0.80–1.25). However, the 90% CI of the AUC_0–24 h, AUC_0–∞ and C_max of the ratio of test to reference drug were within the BE limit, calculated using PBPK modeling when the virtual subjects reached 24 dogs. The results all demonstrated that virtual bioequivalence study can overcome the inequivalence caused by inter-subject variability of the 6 beagle dogs involved in in vivo experiments.
Co-administration of succinylated gelatine with a <sup>99m</sup>Tc-bombesin analogue, effects on pharmacokinetics and tumor uptake
2016, Nuclear Medicine and Biology
Citation Excerpt :
The half-lives (t1/2) calculated from the one-compartment model were 21.0 and 28.9 min for mice and rats, respectively. The interspecies difference in the half-lives are in accordance with literature data, where the elimination time is increased when the pharmacokinetics are scaled up through animal species [50,51]. The differences in the mean residence time (MRTblood) between rats and mice were also in accordance with this observation: 27.1 for mice and 31.1 min for rats.
The bombesin analogue, [^99mTc-GGC]-(Ornithine)₃-BN(2-14), ^99mTc-BN-O, targeting gastrin releasing peptide receptors (GRPrs) on the surface of tumors, was pre-clinically investigated as potential imaging agent for single photon emission computed tomography (SPECT). In addition, the improvement of its pharmacokinetic profile (PK) was investigated through the co-administration of a succinylated gelatin plasma expander (Gelofusine), aiming to reduce its kidney accumulation and enhance its tumor-to-normal tissue contrast ratios. Biodistribution data were collected from normal mice and rats, and PC-3 tumor bearing mice, in reference to its PK, metabolism and tumor uptake. Imaging data were also collected from PC-3 tumor bearing mice. Biodistribution and imaging experiments showed that ^99mTc-BN-O was able to efficiently localize the tumor (5.23 and 7.00% ID/g at 30 and 60 min post injection, respectively), while at the same time it was rapidly cleared from the circulation through the kidneys. HPLC analysis of kidney samples, collected at 60 min p.i. from normal mice and rats, showed that the majority of radioactivity detected was due to intact peptide i.e. 56% for mice and 73% for rats. Co-administration of ^99mTc-BN-O with Gelo resulted in the reduction of kidney uptake in both animal models. The integrated area under the curve (AUC_{30–60 min}) from the concentration–time plots of kidneys was decreased in both mice and rats by 25 and 50%, respectively. In PC-3 tumor bearing mice, an increase of tumor uptake (AUC_tumor increased by 69%) was also observed with Gelo. An improvement in tumor-to-blood and tumor-to-normal tissue ratios was noted in all cases with the exception of the pancreas, which normally expresses GRPr. The results of this preclinical study may also be extended to other similar peptides, which are utilized in prostate cancer imaging and present similar PK profile.
Quantitative prediction of human pharmacokinetics and pharmacodynamics of imigliptin, a novel DPP-4 inhibitor, using allometric scaling, IVIVE and PK/PD modeling methods
2016, European Journal of Pharmaceutical Sciences
Citation Excerpt :
Results from two comprehensive assessments of prediction methods for human clearance, fu corrected intercept method (FCIM-rat, FCIM-dog, and FCIM-monkey) (Tang and Mayersohn, 2005) two species method (TS-r,d and TS-r,m) (Tang et al., 2007) showed that methods employing monkey clearance values produced the best overall predictions.( Lombardo et al., 2013; Ring et al., 2011) In order to understand which species is similar to human in clearance, single species scaling method (SSS-rat, SSS-dog, and SSS-monkey), (Ring et al., 2011) simple allometric scaling method (SAS-r,d,m), (Ring et al., 2011) rule of exponent method (ROE), (Mahmood and Balian, 1996) and hepatic blood flow corrected method (HBF-monkey) were tested. Similarly, top two methods (Øie-Tozer method (Oie and Tozer, 1979; Waters and Lombardo, 2010) and rat-dog-human proportionality equation (log function) (Wajima et al., 2003)) showing the best prediction performance were conducted to predict imigliptin Vss in humans.
To predict the pharmacokinetic/pharmacodynamic (PK/PD) profiles of imigliptin, a novel DPP-4 inhibitor, in first-in-human (FIH) study based on the data from preclinical species.
Imigliptin was intravenously and orally administered to rats, dogs, and monkeys to assess their PK/PD properties. DPP-4 activity was the PD biomarker. PK/PD profiles of sitagliptin and alogliptin in rats and humans were obtained and digitized from literatures. PK/PD profiles of all dose levels for each drug in each species were analyzed using modeling approach. Human CL, V_ss and PK profiles of imigliptin were then predicted using Allometric Scaling (AS), in vitro in vivo extrapolation (IVIVE), and the steady-state plasma drug concentration – mean residence time (C_ss-MRT) methods. In vitro EC₅₀ corrected by f_u and in vivo EC₅₀ in rats corrected by interspecies difference of sitagliptin and alogliptin were utilized separately to predict imigliptin human EC₅₀. The prediction by integrating all above methods was evaluated by comparing observed and simulated PK/PD profiles in healthy subjects.
Full PK/PD profiles in animal were summarized for imigliptin, sitagliptin and alogliptin. Imigliptin CL, V_ss, and F_a were predicted to be 19.1 L/h, 247 L, and 0.81 in humans, respectively. Predicted imigliptin AUCs, AUECs, and E_max in humans were within 0.8–1.2 times of observed values whereas other predicted PK/PD parameters were within 0.5–1.5 times of observed values.
By integrating available preclinical and clinical data, FIH PK/PD profiles of imigliptin could be accurately predicted.
Propofol-induced rno-miR-665 targets BCL2L1 and influences apoptosis in rodent developing hippocampal astrocytes
2015, NeuroToxicology
Propofol exerts neurotoxic effects on the developing mammalian brains, but the underlying molecular mechanism remains unclear. MicroRNAs (miRNAs) are a class of small noncoding RNAs that modulate gene expression at the post-transcriptional level. However, in specific types of neurocytes, the detailed functions of miRNAs were not entirely understood. We investigated the potential role of miRNAs in astrocyte pathogenesis caused by propofol. We performed genome-wide microRNA expression profiling in immature cultured hippocampal astrocytes by microarray analysis and predicted their targets and functions using bioinformatics tools. The functional effects of one differentially expressed miRNA were examined experimentally in relation to astrocyte viability. The results showed that 13 miRNAs were significantly differentially expressed after both short-term exposure to high-concentration propofol (10 μg/ml for 1 h) and long-term exposure to low-concentration propofol (0.9 μg/ml for 48 h), including rno-miR-665, differing significantly between the 2. Bioinformatics predicted putative binding sites for rno-miR-665 existing in the 3′-untranslated region of Bcl-2-like protein 1 BCL2L1 (Bcl-xl) mRNA. Moreover, such relationship was assessed by luciferase reporter assay, qRT-PCR and western blot. Rno-miR-665 which was significantly up-regulated by propofol can suppress BCL2L1 and elevate cleaved caspase-3 expression in immature astrocytes in vitro. Apoptosis of developing hippocampal astrocytes was thus significantly influenced by propofol or rno-miR-665, or both. Taken together, rno-miR-665 is involved in the neurotoxicity induced by propofol via a caspase-3 mediated mechanism by negatively regulating BCL2L1. It might act as an alternative therapeutic target for treatment of neurological disorders in peadiatric prolonged anesthesia or sedation with propofol clinically.
Prospective Predictions of Human Pharmacokinetics for Eighteen Compounds
2015, Journal of Pharmaceutical Sciences
Citation Excerpt :
Modifications can be conducted by applying correction factors to simple allometry methods. For CL predictions, modifications include corrections for maximum life-span potential (MLP), brain weight (BrW),5 application of the “rule of exponents” (ROEs),11 inclusion of in vitro metabolic data,7 or the scaling of unbound CL.4 Compared with conventional simple allometry, allometric methods considering correction factors have improved the prediction accuracies.
Quantitative predictions of pharmacokinetics (PKs) and concentration–time profiles using in vitro and in vivo preclinical data are critical to estimate systemic exposures for first-in-human studies. Prospective prediction accuracies of human PKs for 18 compounds across all Biopharmaceutics Classification System/Biopharmaceutics Drug Disposition Classification System classes were evaluated. The a priori predicted profiles were then compared with clinical profiles. Predictions were conducted using advanced compartmental absorption and transit (ACAT) physiology based PK models. Human intravenous profiles were predicted with in vivo preclinical intravenous data using Wajima formulas. Human oral profiles were generated by combining intravenous PKs together with either physiologically based oral ACAT models utilizing solubility and permeability data or by using the average bioavailability (F) and absorption rate constant (k_a) from preclinical species. Key PK parameters evaluated were the maximum plasma concentration (C_max), the area under the plasma concentration–time curve (AUC), CL/F, and V_dss/F. A decision tree was provided to guide human PK and ACAT predictions. Our prospective human PK prediction methods yielded good prediction results. The predictions were within a twofold error for 80% (C_max), 65% (AUC), 65% (CL/F), and 80% (V_z/F) of the compounds. The methods described can be readily implemented with available in vitro and in vivo data during early drug development. © 2015 Wiley Periodicals, Inc. and the American Pharmacists Association.
Preclinical Pharmacokinetics and Translational Pharmacokinetic/Pharmacodynamic Modeling of M8891, a Potent and Reversible Inhibitor of Methionine Aminopeptidase 2
2023, Pharmaceutical Research

View all citing articles on Scopus

View full text

Research ArticlesInterspecies Scaling: Predicting Pharmacokinetic Parameters of Antiepileptic Drugs in Humans from Animals with Special Emphasis on Clearance

Abstract

J. Pharm. Sci.

J. Pharm. Sci.

J. Pharm. Sci.

J. Pharmacokinet. Biopharm.

J. Pharmacokinet. Biopharm.

Drug Metab. Rev.

J. Pharmacol. Exp. Ther.

J. Pharmacol. Exp. Ther.

Arch. Int. Pharma-codyn.

J. Appl. Toxicol.

Research Articles
Interspecies Scaling: Predicting Pharmacokinetic Parameters of Antiepileptic Drugs in Humans from Animals with Special Emphasis on Clearance